We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Dual Inhibition of P-gp and BCRP Improves Oral Topotecan Bioavailability in Rodents.
- Authors
Lee, Jaeok; Kang, Jiyeon; Kwon, Na-Yun; Sivaraman, Aneesh; Naik, Ravi; Jin, So-Young; Oh, A. Reum; Shin, Jae-Ho; Na, Younghwa; Lee, Kyeong; Lee, Hwa-Jeong; Lee, Yonghyun
- Abstract
P-glycoprotein (P-gp) inhibition has been studied to overcome multidrug resistance in cancer chemotherapy but failed in clinical trials due to low/toxic effects. Recently, a dual modulation of transporters and natural derivatives have been examined to surmount this limitation. We examined breast cancer resistance protein (BCRP) inhibition in vitro and in vivo by P-gp inhibitors derived from natural compounds in previous studies. P-gp inhibitors increased the accumulation of the anticancer drug, topotecan (TPT)—a substrate of P-gp and BCRP, albeit with higher affinity for BCRP—in BCRP-overexpressing cells, resulting in cell death. These dual inhibitors, when orally co-administered with TPT, enhanced TPT bioavailability with slightly reduced total oral clearance (Clt/F) in rats. In xenograft mice, they strengthened oral TPT-induced tumor reduction with no alterations in body weight. Moreover, we investigated the effects of an oral drug formulation (Cremophor® EL, Tween® 80, and polyethylene glycol 400) on the transporters function. The excipients increased TPT accumulation in P-gp- or BCRP-overexpressing cells. Oral TPT bioavailability was higher with the formulation than with a control, as shown by the increases in the maximum plasma concentration (Cmax) and the area under the plasma concentration–time curve from zero to infinity (AUCINF) (p< 0.01). Therefore, oral TPT bioavailability was enhanced by P-gp/BCRP dual inhibition, which resulted in a formulation-mediated increase in absorption and decrease in elimination, and a dual inhibitor-mediated decrease in elimination. These results suggest that the combination of dual inhibition by a natural derivative and the drug formulation can be a useful clinical approach.
- Subjects
BIOAVAILABILITY; TOPOTECAN; CANCER chemotherapy; BREAST cancer; DRUG derivatives; POLYETHYLENE glycol
- Publication
Pharmaceutics, 2021, Vol 13, Issue 4, p559
- ISSN
1999-4923
- Publication type
Article
- DOI
10.3390/pharmaceutics13040559